Sirolimus for progressive neurofibromatosis type 1-associated plexiformneurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study (vol 17, pg 596, 2015)

被引：0
|
作者：
Weiss
机构：
来源：
NEURO-ONCOLOGY | 2015年 / 17卷 / 06期
关键词：
D O I：
10.1093/neuonc/nov068
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：905 / 905
页数：1
相关论文
共 20 条
  • [1] Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study
    Weiss, Brian
    Widemann, Brigitte C.
    Wolters, Pamela
    Dombi, Eva
    Vinks, Alexander
    Cantor, Alan
    Perentesis, John
    Schorry, Elizabeth
    Ullrich, Nicole
    Gutmann, David H.
    Tonsgard, James
    Viskochil, David
    Korf, Bruce
    Packer, Roger J.
    Fisher, Michael J.
    NEURO-ONCOLOGY, 2015, 17 (04) : 596 - 603
  • [2] A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study
    Ullrich, Nicole J.
    Prabhu, Sanjay P.
    Reddy, Alyssa T.
    Fisher, Michael J.
    Packer, Roger
    Goldman, Stewart
    Robison, Nathan J.
    Gutmann, David H.
    Viskochil, David H.
    Allen, Jeffrey C.
    Korf, Bruce
    Cantor, Alan
    Cutter, Gary
    Thomas, Coretta
    Perentesis, John P.
    Mizuno, Tomoyuki
    Vinks, Alexander A.
    Manley, Peter E.
    Chi, Susan N.
    Kieran, Mark W.
    NEURO-ONCOLOGY, 2020, 22 (10) : 1527 - 1535
  • [3] TOLERABILITY OF THE MTOR INHIBITOR SIROLIMUS IN A PHASE II STUDY FOR NEUROFIBROMATOSIS TYPE 1 (NF1)-ASSOCIATED PLEXIFORM NEUROFIBROMAS: A NEUROFIBROMATOSIS CONSORTIUM STUDY
    Weiss, B.
    Widemann, B. C.
    Cantor, A.
    Perentesis, J.
    Vinks, A.
    Ullrich, N.
    Gutmann, D.
    Korp, B.
    Packer, R.
    Fisher, M. J.
    NEURO-ONCOLOGY, 2010, 12 (06) : II85 - II85
  • [4] PHASE 2 STUDY OF THE MTOR INHIBITOR SIROLIMUS FOR PROGRESSIVE NF1-ASSOCIATED PLEXIFORM NEUROFIBROMAS (PN): A NEUROFIBROMATOSIS CLINICAL TRIALS CONSORTIUM STUDY
    Fisher, Michael J.
    Widemann, Brigitte C.
    Dombi, Eva
    Wolters, Pamela
    Cantor, Alan
    Vinks, Alexander
    Parentesis, John
    Ullrich, Nicole
    Gutmann, David
    Viskochil, David
    Tonsgard, James
    Korf, Bruce
    Packer, Roger
    Weiss, Brian
    NEURO-ONCOLOGY, 2014, 16 : 129 - 129
  • [5] PHASE II STUDY OF THE MTOR INHIBITOR SIROLIMUS FOR NON-PROGRESSIVE NF1-ASSOCIATED PLEXIFORM NEUROFIBROMAS: A NEUROFIBROMATOSIS CONSORTIUM STUDY
    Weiss, B.
    Fisher, M. J.
    Dombi, E.
    Cantor, A.
    Vinks, A.
    Korf, B.
    Schorry, E.
    Gutmann, D.
    Packer, R.
    Widemann, B. C.
    NEURO-ONCOLOGY, 2010, 12 (06) : II43 - II43
  • [6] Phase II study of the mTOR inhibitor sirolimus for nonprogressive NF1-associated plexiform neurofibromas: A Neurofibromatosis Consortium study.
    Widemann, B. C.
    Fisher, M. J.
    Dombi, E.
    Cantor, A.
    Vinks, S.
    Korf, B.
    Schorry, E.
    Gutmann, D.
    Packer, R.
    Weiss, B. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] MEK INHIBITOR BINIMETINIB SHOWS CLINICAL ACTIVITY IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMAS: A REPORT FROM PNOC AND THE NF CLINICAL TRIALS CONSORTIUM
    Mueller, Sabine
    Reddy, Alyssa T.
    Dombi, Eva
    Allen, Jeffrey
    Packer, Roger
    Clapp, Wade
    Goldman, Stewart
    Schorry, Elizabeth
    Tonsgard, James
    Blakeley, Jaishri
    Ullrich, Nicole J.
    Gross, Andrea
    Walsh, Karin
    Thomas, Coretta
    Edwards, Lloyd
    Prados, Michael
    Korf, Bruce
    Fisher, Michael J.
    NEURO-ONCOLOGY, 2020, 22 : 420 - 421
  • [8] Treatment of neurofibromatosis type 1 (NF1)-related plexiform neurofibromas PN) with cabozantinib (XL184): A Neurofibromatosis Clinical Trials Consortium Phase II trial
    Shih, Chie-Schin
    Blakeley, Jaishri
    Clapp, D. Wade
    Armstrong, Amy E.
    Wolters, Pam
    Dombi, Eva
    Cutter, Gary
    Ullrich, Nicole J.
    Allen, Jeffrey
    Packer, Roger
    Goldman, Stewart
    Gutmann, David H.
    Plotkin, Scott
    Rosser, Tena
    Robertson, Kent
    Widemann, Brigitte
    Rhodes, Steven
    Angus, Steven
    Johnson, Gary
    Korf, Bruce
    Fisher, Michael J.
    CANCER RESEARCH, 2019, 79 (13)
  • [9] Sirolimus for Non-Progressive NF1-Associated Plexiform Neurofibromas: An NF Clinical Trials Consortium Phase II Study
    Weiss, Brian
    Widemann, Brigitte C.
    Wolters, Pamela
    Dombi, Eva
    Vinks, Alexander A.
    Cantor, Alan
    Korf, Bruce
    Perentesis, John
    Gutmann, David H.
    Schorry, Elizabeth
    Packer, Roger
    Fisher, Michael J.
    PEDIATRIC BLOOD & CANCER, 2014, 61 (06) : 982 - 986
  • [10] Multicenter, phase 2 study of bevacizumab in children and adults with neurofibromatosis 2 and progressive vestibular schwannomas: an NF Clinical Trials Consortium study
    Plotkin, Scott
    Tonsgard, James
    Ullrich, Nicole
    Allen, Jeffrey
    Blakeley, Jaishri
    Rosser, Tena
    Clapp, David
    Campion, Jian
    Fisher, Michael
    Cutter, Gary
    Korf, Bruce
    Packer, Roger
    Thomas, Coretta
    Karajannis, Matthias
    NEUROLOGY, 2018, 90
12